Serine protease in fibrinolysis pathway (PLG, tPA, uPA)

Plasmin is a serine protease that serves as the central enzyme in the fibrinolytic pathway, catalyzing the degradation of fibrin clots to maintain vascular patency after injury. Its precursor, plasminogen, is converted to active plasmin by tissue plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA), both of which are also serine proteases[1][3][5]. These enzymes play key roles not only in fibrinolysis but also in tissue remodeling, inflammation, and modulation of immune responses. Tight regulation of their activity is maintained by endogenous inhibitors (e.g., SERPINs) to prevent pathological bleeding or thrombosis. Therapeutically, recombinant tPA and urokinase are used in the management of acute thrombotic events such as myocardial infarction, ischemic stroke, and pulmonary embolism, but these agents carry a high risk of bleeding. Aberrations in this pathway are associated with a wide range of diseases, including cardiovascular disorders, cancer progression, neurodegenerative diseases, and inflammatory conditions[2][4][5]. Additional Note: The query is overly general—“serine protease in fibrinolysis pathway” is a functional class, not a single molecular entity. The most precise canonical target to assign within drug discovery or clinical context is *plasmin*, or, for therapeutic modulation, *tPA* or *uPA*[1][3][5].

Other names

Plasminogen (zygogenic precursor of plasmin)Tissue plasminogen activator (tPA)Urokinase-type plasminogen activator (uPA)Fibrinolytic serine proteases

Enzymatic cleavage of plasminogen to plasmin (tPA, uPA) Plasmin cleaves fibrin within blood clots, dissolving thrombi Inhibition of plasmin formation/action (antifibrinolytics)